| Literature DB >> 26933947 |
Shuangshuang Li1,2, Shiqi Wang1,2, Zhenhua Guo1,2, Huan Wu1,2, Xianqing Jin1,2, Yi Wang2, Xiaoqing Li2, Shaoyan Liang1.
Abstract
Hirschsprung's disease (HSCR), the most common congenital malformation of the gut, is regulated by multiple signal transduction pathways. Several components of these pathways are important targets for microRNAs (miRNAs). Multiple miRNAs have been associated with the pathophysiology of HSCR, and serum miRNAs profiles of HSCR patients have been reported, but miRNA expression in HSCR colon tissue is almost completely unexplored. Using microarray technology, we screened colon tissue to detect miRNAs whose expression profiles were altered in HSCR and identify targets of differentially expressed miRNAs. Following filtering of low-intensity signals, data normalization, and volcano plot filtering, we identified 168 differentially expressed miRNAs (104 up-regulated and 64 down-regulated). Fifty of these mRNAs represent major targets of dysegulated miRNAs and may thus important roles in the pathophysiology of HSCR. Pathway analysis revealed that 7 of the miRNA targets encode proteins involved in regulation of cell proliferation and migration via RET and related signaling pathways (MAPK and PI3K/AKT). Our results identify miRNAs that play key roles in the pathophysiology of the complex multi-factorial disease HSCR.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26933947 PMCID: PMC4774952 DOI: 10.1371/journal.pone.0150222
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Correlation coefficient matrix.
| 2 | 3con | 4con | 10con | 6 | 21 | |
| 2 | 1 | 0.811644 | 0.933567 | 0.928441 | 0.926646 | 0.927493 |
| 3con | 0.811644 | 1 | 0.802831 | 0.855139 | 0.790199 | 0.821824 |
| 4con | 0.933567 | 0.802831 | 1 | 0.912029 | 0.980958 | 0.965628 |
| 10con | 0.928441 | 0.855139 | 0.912029 | 1 | 0.899282 | 0.909014 |
| 6 | 0.926646 | 0.790199 | 0.980958 | 0.899282 | 1 | 0.971962 |
| 21 | 0.927493 | 0.821824 | 0.965628 | 0.909014 | 0.971962 | 1 |
| 3 | 4 | 10 | 13 | 16 | 20 | |
| 3 | 1 | 0.741872 | 0.735071 | 0.778827 | 0.776793 | 0.765929 |
| 4 | 0.741872 | 1 | 0.899341 | 0.944584 | 0.944766 | 0.965464 |
| 10 | 0.735071 | 0.899341 | 1 | 0.887571 | 0.901474 | 0.897829 |
| 13 | 0.778827 | 0.944584 | 0.887571 | 1 | 0.982051 | 0.983028 |
| 16 | 0.776793 | 0.944766 | 0.901474 | 0.982051 | 1 | 0.985639 |
| 20 | 0.765929 | 0.965464 | 0.897829 | 0.983028 | 0.985639 | 1 |
| con | exp | |||||
| con | 1 | 0.896708 | ||||
| exp | 0.896708 | 1 |
Table 1 shows the correlation matrix for the replicate samples used in this study.
Fig 1Scatter-plot to assess inter-chip variation.
A scatter-plot was used to assess variation between chips. The axes of the scatter-plot show normalized signal values.
Fig 2Heat map showing differentially expressed miRNAs.
(a) Unsupervised hierarchic clustering of miRNAs differentially expressed between stenotic segments from HSCR patients and normal segments was performed using the Pearson correlation coefficient. Each row corresponds to one miRNA, and each column corresponds to one sample. Stenotic colon segments from HSCR patients are labeled as 3, 4, 10, 13, 16 and 20, control colon segments from HSCR patients are labeled as 3con, 4con, 10con and normal tissues from healthy subjects are labeled as 2, 6, and 21. (b) Unsupervised hierarchical clustering analysis of miRNAs targeting RET and RET-regulating pathways.
Summary of differentially expressed miRNAs.
| Normalized expression level | ||||
|---|---|---|---|---|
| miRNA ID | Mean of con group | Mean of exp group | -Fold change | P-value |
| hsa-miR-142-3p | 1.552452 | 22.20496 | 14.30315 | 0.022786 |
| hsa-miR-142-5p | 0.434593 | 3.342842 | 7.691894 | 0.014472 |
| hsa-miR-146b-5p | 0.273015 | 1.11891 | 4.098344 | 0.008892 |
| hsa-miR-338-3p | 0.168553 | 0.592369 | 3.51444 | 1.45E-05 |
| hsa-miR-369-3p | 0.079203 | 0.184768 | 2.332848 | 0.040346 |
| hsa-miR-429 | 0.212249 | 0.632613 | 2.980516 | 0.001719 |
| hsa-miR-519b-3p | 0.042262 | 0.096649 | 2.286893 | 0.002715 |
| hsa-miR-614 | 0.086465 | 0.190521 | 2.203436 | 0.003912 |
| hsa-miR-654-3p | 0.061961 | 0.12517 | 2.020138 | 0.021811 |
| hsa-miR-938 | 0.120295 | 0.245218 | 2.038465 | 0.004496 |
| hsa-miR-107 | 7.237026 | 2.929471 | 0.404789 | 0.022436 |
| hsa-miR-638 | 6.694976 | 3.012428 | 0.449953 | 0.002173 |
| hsa-miR-885-3p | 0.518701 | 0.226666 | 0.436987953 | 0.002046 |
miRNAs (differentially expressed [P ≤ 0.05, Student t test] in stenotic colon segment tissues versus normal colon tissues) that target experimentally validated mRNAs related to HSCR pathology.
List of experimentally validated mRNA targets of differentially expressed miRNAs.
| Gene symbol | Gene name | Targeting miRNA name |
|---|---|---|
| angiotensin I converting enzyme | hsa-mir-429 | |
| adenosine deaminase, RNA-specific | hsa-mir-142-5p | |
| adenosine deaminase, RNA-specific, B1 | hsa-mir-142-5p | |
| v-akt murine thymoma viral oncogene homolog 1 | hsa-mir-142-3p | |
| anti-Mullerian hormone | hsa-mir-429 | |
| amyloid P component, serum | hsa-mir-142-5p | |
| B-cell CLL/lymphoma 2 | hsa-mir-146b-5p | |
| brain-derived neurotrophic factor | hsa-mir-107 | |
| breast cancer 1, early onset | hsa-mir-369-3p,hsa-mir-146b-5p,hsa-mir-638 | |
| CD4 molecule | hsa-mir-614,hsa-mir-146b-5p,hsa-mir-142-3p, hsa-mir-142-5p | |
| CD68 molecule | hsa-mir-146b-5p | |
| CD79a molecule, immunoglobulin-associated alpha | hsa-mir-429,hsa-mir-146b-5p | |
| CD8a molecule | hsa-mir-614,hsa-mir-146b-5p,hsa-mir-142-3p, hsa-mir-142-5p | |
| cyclin-dependent kinase inhibitor 1A (p21, Cip1) | hsa-mir-654-3p,hsa-mir-519b-3p,hsa-mir-338-3p,hsa-mir-146b-5p,hsa-mir-142-3p | |
| cyclin-dependent kinase inhibitor 2A | hsa-mir-885-3p | |
| cAMP responsive element binding protein 1 | hsa-mir-142-3p | |
| cell surface receptor for the CXC chemokine PBSF/SDF-1 | has-mir-142-3p, has-146b-5p | |
| Dystrophin | hsa-mir-146b-5p | |
| E2F transcription factor 1 | hsa-mir-107 | |
| argonaute RISC catalytic component 2 | hsa-mir-107 | |
| fibroblast growth factor 2 | hsa-mir-146b-5p | |
| FBJ murine osteosarcoma viral oncogene homolog | hsa-mir-146b-5p | |
| GLI family zinc finger 1 | hsa-mir-429 | |
| GLI family zinc finger 3 | hsa-mir-429 | |
| indian hedgehog | hsa-mir-429 | |
| interleukin 1, beta | hsa-mir-146b-5p, hsa-mir-142-5p | |
| interleukin 6 | hsa-mir-146b-5p | |
| integrin, alpha 3 | hsa-mir-142-3p | |
| jun proto-oncogene | hsa-mir-146b-5p, hsa-mir-142-3p | |
| v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog | hsa-mir-107 | |
| mitogen-activated protein kinase kinase 1 | hsa-mir-146b-5p | |
| mitogen-activated protein kinase 1 | hsa-mir-146b-5p | |
| mitogen-activated protein kinase 3 | hsa-mir-146b-5p | |
| methyl CpG binding protein 2 | hsa-mir-146b-5p | |
| microphthalmia-associated transcription factor | hsa-mir-429 | |
| v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog | hsa-mir-429 | |
| neurofibromin 2 (merlin) | hsa-mir-885-3p, | |
| phospholipase C, gamma 1 | hsa-mir-429 | |
| Proopiomelanocortin | hsa-mir-142-3p | |
| patched 1 | hsa-mir-146b-5p | |
| phosphatase and tensin homolog | hsa-mir-429 | |
| receptor tyrosine kinase | hsa-mir-146b-5p | |
| sonic hedgehog | hsa-mir-429 | |
| snail family zinc finger 2 | hsa-mir-429 | |
| SRY (sex determining region Y)-box 10 | hsa-mir-338-3p | |
| transforming growth factor, beta 1 | hsa-mir-938,hsa-mir-429 | |
| tumor necrosis factor | hsa-mir-369-3p,hsa-mir-146b-5p,hsa-mir-142-5p | |
| tumor protein p53 | hsa-mir-429,hsa-mir-146b-5p,hsa-mir-142-3p | |
| zinc finger E-box binding homeobox 1 | hsa-mir-429 | |
| zinc finger E-box binding homeobox 3 | hsa-mir-429 |
Fifty experimental valided miRNA targets associated with HSCR were identified using miRWalk software and GoGene and NCBI PubMed databases.
Fig 3DAVID KEGG pathway analysis.
KEGG pathway analysis of the list of 50 miRNA targets. The vertical axis provides the names of the most significantly overrepresented pathways (P < 0.01), whereas the horizontal axis shows the -2log10(P), where P was calculated based on Fisher’s exact test. The ratio (red) represents the numbers of genes in a given pathway that meet the cutoff criteria, divided by the total number of genes in that pathway.
Fig 4Quantitative RT-PCR analysis.
Quantitative RT-PCR analysis of miRNAs targeting RET and its related pathways in76 stenotic segments and matched control tissue from HSCR patients, *, P < 0.05 versus control group, **, P < 0.01 versus control group.
Fig 5Changes in the expression of RET members and molecules associated with RET-related signaling pathways in stenotic and control colon tissues.
Compared with control colon tissues, stenotic colon tissues showed significantly down-regulated expression of RET and molecules involved in RET-associated signaling pathways (*p< 0.05). Thirty-two stenotic and control colon tissues from patients with HSCR (aged 3 months to 4 years) were used for RNA extraction and qRT-PCR analysis.
Fig 6Deregulation of RET and its regulating signaling pathways in HSCR patients.
Genes are shown in the chart in round shape. miRNAs are shown in the chart in hexagon. Continuous or dashed lines stand for direct or indirect relationship.